Its role Owner
Roche (Roche Holding AG) is a global healthcare company headquartered in Basel, Switzerland, focused on the research, development, and manufacturing of pharmaceuticals and diagnostics. The group operates through two core divisions—Pharmaceuticals and Diagnostics—and includes subsidiaries such as Genentech in the United States and Chugai in Japan.
For the chemical and life sciences value chain, Roche develops small‑molecule medicines and active pharmaceutical ingredients (APIs) alongside a broad portfolio of biologics, including monoclonal and bispecific antibodies. Its capabilities span process chemistry, analytical development, scale‑up, and GMP manufacturing, as well as large‑scale cell culture, purification, and fill‑finish operations. The Diagnostics division provides in vitro diagnostic systems, reagents, and molecular testing technologies. Roche’s therapeutic focus areas include oncology, immunology, infectious diseases, neuroscience, and ophthalmology. The company maintains a global R&D and manufacturing network and emphasizes regulatory compliance, quality, and reliable supply across its operations.
Also known as Roche Group, Roche Holding AG, Roche Diagnostics GmbH, Roche Diagnostics, F. Hoffmann-La Roche and 1 more.
chemXplore tracks 1 project involving Roche.
A first‑in‑class IL‑6R inhibitor and the first and only at‑home subcutaneous treatment option for thyroid eye disease.
FDA clears the first at‑home subcutaneous IL‑6R treatment for TED; Phase III SatraGO‑2 showed marked proptosis and diplopia improvements and safety consistent with prior NMOSD data.
Sustained vision gains and reduced macular thickness at Week 52; ~2/3 avoided retreatment after Week 16, most needing only one additional injection; safety profile consistent.
Vamikibart showed sustained vision gains and reduced macular thickness at 52 weeks in MEERKAT and SANDCAT; FDA has accepted the BLA with a decision due by July 2027.
FDA backs first adjuvant immunotherapy regimen for stage III dMMR colon cancer after ATOMIC showed a 50% reduction in recurrence or death with Tecentriq added to chemotherapy.
VOYAGER shows Vabysmo yields vision gains, marked CST reductions and reduced retinal fluid across nAMD, DME and RVO in routine practice, with no new safety signals.
VOYAGER real-world data show Vabysmo improves vision and reduces retinal thickness across wet AMD, DME and RVO, with rapid anatomical drying and no new safety signals.
evERA Phase III: giredestrant+everolimus doubled median PFS in ESR1‑mutated patients and improved ITT PFS; OS immature; manageable safety; FDA review dates set for Nov 30 and Dec 18, 2026.
active all projects
